Epub 2013 Nov 6.
Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy
Collaborators
- PMID: 24214521
Item in Clipboard
Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy
J Popul Ther Clin Pharmacol.
2013.
Abstract
This guideline is intended to provide a basis for informed decision-making regarding genetic testing to identify those individuals who will not benefit from codeine therapy, as well as those who are at an increased risk for codeine-induced toxicity. This guideline addresses the following key questions: 1) Should genetic testing for CYP2D6 be performed in patients prior to the initiation of codeine therapy? 2) How should patients with an indication for codeine therapy be managed based on their genotyping results for CYP2D6?
Similar articles
-
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.Clin Pharmacol Ther. 2014 Apr;95(4):376-82. doi: 10.1038/clpt.2013.254. Epub 2014 Jan 23. Clin Pharmacol Ther. 2014. PMID: 24458010 Free PMC article.
-
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.Clin Pharmacol Ther. 2012 Feb;91(2):321-6. doi: 10.1038/clpt.2011.287. Epub 2011 Dec 28. Clin Pharmacol Ther. 2012. PMID: 22205192 Free PMC article.
-
Pharmacogenomics: why standard codeine doses can have serious toxicities or no therapeutic effect.Oncol Nurs Forum. 2013 Jul;40(4):322-4. doi: 10.1188/13.ONF.322-324. Oncol Nurs Forum. 2013. PMID: 23803265 No abstract available.
-
[Problem forte--is paracetamol-codeine combination rational?].Tidsskr Nor Laegeforen. 2004 Aug 26;124(16):2084-7. Tidsskr Nor Laegeforen. 2004. PMID: 15334119 Review. Norwegian.
-
Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.Drug Metab Pharmacokinet. 2014;29(1):29-43. doi: 10.2133/dmpk.dmpk-13-rv-032. Epub 2013 Jun 11. Drug Metab Pharmacokinet. 2014. PMID: 23759977 Review.
Cited by
-
Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy.J Mol Diagn. 2021 Sep;23(9):1047-1064. doi: 10.1016/j.jmoldx.2021.05.013. Epub 2021 Jun 10. J Mol Diagn. 2021. PMID: 34118403 Free PMC article. Review.
-
Haplotype phasing of CYP2D6: an allelic ratio method using Agena MassARRAY data.Transl Psychiatry. 2024 Feb 12;14(1):91. doi: 10.1038/s41398-024-02809-y. Transl Psychiatry. 2024. PMID: 38346976 Free PMC article.
-
Gene-based drug therapy in children.Paediatr Child Health. 2023 Jun 6;28(4):205-251. doi: 10.1093/pch/pxad002. eCollection 2023 Jul. Paediatr Child Health. 2023. PMID: 37287477 Free PMC article. Review.
-
Les tests pharmacogénomiques: Améliorer le recours personnalisé aux médicaments pour les patients.Can Fam Physician. 2020 Apr;66(4):247-249. Can Fam Physician. 2020. PMID: 32273408 Free PMC article. French. No abstract available.
-
Pharmacogenomics-assisted treatment versus standard of care in schizophrenia: a systematic review and meta-analysis.BMC Psychiatry. 2024 Oct 8;24(1):663. doi: 10.1186/s12888-024-06104-4. BMC Psychiatry. 2024. PMID: 39379847 Free PMC article.